Mark Andrew Wilson Sells 33,402 Shares of Nektar Therapeutics (NASDAQ:NKTR) Stock

Nektar Therapeutics (NASDAQ:NKTR) insider Mark Andrew Wilson sold 33,402 shares of the company’s stock in a transaction dated Monday, December 23rd. The stock was sold at an average price of $0.90, for a total transaction of $30,061.80. Following the transaction, the insider now owns 351,892 shares in the company, valued at approximately $316,702.80. This trade represents a 8.67 % decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link.

Nektar Therapeutics Trading Down 0.2 %

NASDAQ:NKTR opened at $0.95 on Friday. The firm has a market capitalization of $175.09 million, a price-to-earnings ratio of -1.13 and a beta of 0.57. Nektar Therapeutics has a 1-year low of $0.48 and a 1-year high of $1.93. The business’s 50-day moving average price is $1.14 and its two-hundred day moving average price is $1.22.

Institutional Investors Weigh In On Nektar Therapeutics

Hedge funds have recently bought and sold shares of the company. Victory Capital Management Inc. bought a new position in shares of Nektar Therapeutics during the 2nd quarter valued at about $29,000. Valence8 US LP acquired a new stake in Nektar Therapeutics during the 3rd quarter worth approximately $34,000. Intech Investment Management LLC bought a new position in Nektar Therapeutics in the third quarter valued at approximately $41,000. XTX Topco Ltd acquired a new position in shares of Nektar Therapeutics in the third quarter valued at approximately $46,000. Finally, Erste Asset Management GmbH acquired a new position in shares of Nektar Therapeutics in the third quarter valued at approximately $61,000. 75.88% of the stock is currently owned by institutional investors and hedge funds.

Analysts Set New Price Targets

Several analysts have recently commented on NKTR shares. Piper Sandler began coverage on shares of Nektar Therapeutics in a research note on Monday, November 4th. They set an “overweight” rating and a $7.00 price target on the stock. HC Wainwright started coverage on Nektar Therapeutics in a research report on Tuesday, December 10th. They issued a “buy” rating and a $6.50 price objective on the stock. Finally, BTIG Research restated a “buy” rating and set a $4.00 target price on shares of Nektar Therapeutics in a research report on Monday, September 30th. Three analysts have rated the stock with a hold rating and four have issued a buy rating to the company’s stock. According to MarketBeat.com, Nektar Therapeutics has a consensus rating of “Moderate Buy” and an average target price of $4.10.

About Nektar Therapeutics

Nektar Therapeutics, a biopharmaceutical company, focuses on discovering and developing medicines in the field of immunotherapy in the United States and internationally. The company is developing rezpegaldesleukin, a cytokine Treg stimulant that is in phase 2 clinical trial for the treatment of systemic lupus erythematosus and ulcerative colitis, as well as phase 2b clinical trial to treat atopic dermatitis and psoriasis; and NKTR-255, an IL-15 receptor agonist, which is in phase 1 clinical trial to boost the immune system's natural ability to fight cancer.